PTCT - PTC Therapeutics Inc Stock Price, Fair Value and News

32.15USD+0.01 (+0.03%)Market Closed

Market Summary

USD32.15+0.01

Market Closed

0.03%

PTCT Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

PTCT Stock Price

View Fullscreen

PTCT RSI Chart

PTCT Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

-4.26

Price/Sales (Trailing)

2.66

EV/EBITDA

-5.91

Price/Free Cashflow

-28.7

PTCT Price/Sales (Trailing)

PTCT Profitability

EBT Margin

-69.63%

Return on Equity

64.8%

Return on Assets

-32.37%

Free Cashflow Yield

-3.48%

PTCT Fundamentals

PTCT Revenue

Revenue (TTM)

927.6M

Rev. Growth (Yr)

-4.66%

Rev. Growth (Qtr)

-31.57%

PTCT Earnings

Earnings (TTM)

-579.2M

Earnings Growth (Yr)

34.1%

Earnings Growth (Qtr)

41.22%

Breaking Down PTCT Revenue

Last 7 days

26.5%

Last 30 days

10.5%

Last 90 days

23.2%

Trailing 12 Months

-41.7%

How does PTCT drawdown profile look like?

PTCT Financial Health

Current Ratio

2.03

Debt/Equity

-0.32

Debt/Cashflow

-0.2

PTCT Investor Care

Shares Dilution (1Y)

3.38%

Diluted EPS (TTM)

-7.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	927.6M	0	0	0
2023	770.4M	818.7M	798.2M	937.8M
2022	569.4M	618.2M	696.6M	698.8M
2021	430.4M	471.9M	492.2M	538.6M
2020	321.7M	311.4M	358.4M	380.8M
2019	261.8M	278.5M	296.4M	307.0M
2018	203.7M	224.5M	236.3M	264.2M
2017	90.3M	122.5M	141.3M	174.1M
2016	48.2M	57.0M	70.2M	82.7M
2015	23.5M	28.6M	36.7M	36.8M
2014	36.8M	31.6M	17.0M	25.2M
2013	28.6M	27.8M	36.9M	34.7M
2012	113.1M	115.9M	36.7M	33.9M
2011	0	0	0	105.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of PTC Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	klein matthew b.	sold	-83,668	24.894	-3,361	chief executive officer
Apr 17, 2024	pauwels eric	sold	-19,781	25.135	-787	chief executive officer
Apr 17, 2024	klein matthew b.	sold	-32,851	25.135	-1,307	chief executive officer
Apr 02, 2024	golden lee scott	sold	-14,922	28.37	-526	evp & chief medical officer
Feb 15, 2024	steele glenn jr md phd	acquired	-	-	4,000	-
Feb 15, 2024	golden lee scott	acquired	-	-	22,600	chief medical officer
Feb 15, 2024	utter christine marie	acquired	-	-	16,900	svp, chief accounting officer
Feb 15, 2024	schmertzler michael	acquired	-	-	8,000	-
Feb 15, 2024	boulding mark elliott	acquired	-	-	21,200	exec. vp and clo
Feb 15, 2024	gravier pierre	acquired	-	-	22,100	chief financial officer

Which funds bought or sold PTCT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 29, 2024	China Universal Asset Management Co., Ltd.	added	69.04	188,000	429,000	0.06%
Apr 29, 2024	Allspring Global Investments Holdings, LLC	new	-	45,788	45,788	-%
Apr 29, 2024	PRINCIPAL FINANCIAL GROUP INC	added	1.66	35,172	516,755	-%
Apr 26, 2024	PINNACLE ASSOCIATES LTD	added	1.77	315,464	4,565,330	0.07%
Apr 25, 2024	nVerses Capital, LLC	new	-	58,180	58,180	0.14%
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	797	15,156	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	added	6.34	45,445	416,540	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	138	2,619	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-7.86	-195,890	6,929,500	-%
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	22,000	695,000	-%

Are Funds Buying or Selling PTCT?

Are funds buying PTCT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PTCT

No. of Funds

Unveiling PTC Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.10%	6,864,000	SC 13G
Feb 14, 2024	rtw investments, lp	9.8%	7,423,970	SC 13G/A
Feb 13, 2024	vanguard group inc	11.66%	8,800,843	SC 13G/A
Feb 08, 2024	wellington management group llp	13.01%	9,816,603	SC 13G/A
Jan 24, 2024	state street corp	6.14%	4,633,955	SC 13G/A
Jan 10, 2024	fmr llc	-	0	SC 13G/A
Jan 08, 2024	blackrock inc.	10.2%	7,668,871	SC 13G/A
Nov 13, 2023	fmr llc	-	0	SC 13G/A
Oct 30, 2023	camber capital management lp	5.31%	2,013	SC 13G
Feb 14, 2023	rtw investments, lp	7.7%	5,615,387	SC 13G/A

Recent SEC filings of PTC Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 25, 2024	10-Q	Quarterly Report
Apr 25, 2024	8-K	Current Report
Apr 22, 2024	4	Insider Trading
Apr 19, 2024	144	Notice of Insider Sale Intent
Apr 19, 2024	4	Insider Trading
Apr 19, 2024	4	Insider Trading
Apr 17, 2024	144	Notice of Insider Sale Intent
Apr 17, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to PTC Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.1B	6.8B	3.52%	-17.31%	-8.94	6.15	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-3.68%	-28.69%	-41.18	9.92	76.23%	61.08%
BMRN	15.3B	2.5B	-7.53%	-16.73%	74.64	6.2	13.74%	186.89%
INCY	11.7B	3.8B	-8.64%	-30.91%	15.68	3.1	8.58%	129.81%
MID-CAP
APLS	5.3B	396.6M	-24.84%	-46.72%	-10.08	13.43	425.83%	18.94%
BBIO	4.5B	-	-17.14%	78.66%	-6.9	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.57%	4.22%	-14.61	12.91	440.80%	-27.84%
ARWR	2.8B	240.7M	-20.91%	-36.67%	-9.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-9.63%	-23.17%	-44.93	3.79	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-5.58%	-11.16%	24.84	4.45	85.90%	-14.05%
NVAX	606.0M	983.7M	-9.41%	-43.91%	-1.11	0.62	-50.36%	17.16%
CRBP	388.7M	881.7K	-5.61%	336.79%	-8.71	466.16	-77.61%	-5.33%
INO	267.6M	4.9M	-17.51%	25.55%	-1.98	54.99	-54.97%	51.71%
IBIO	6.0M	2.1M	-57.88%	56.88%	-0.22	2.14	-13.45%	66.37%

PTC Therapeutics Inc News

Latest updates

PTC Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-31.6%	210,118,000	307,056,000	196,576,000	213,808,000	220,382,000	167,412,500	217,127,000	165,526,000	148,735,000	165,230,500	138,743,000	116,676,000	117,942,000	118,864,000	118,404,000	75,239,000	68,259,000	96,459,000	71,416,000	85,522,000	53,583,000
Operating Expenses	-15.2%	255,571,000	301,236,000	314,740,000	423,351,000	337,997,000	367,752,000	285,314,000	257,888,000	235,257,000	249,958,500	231,819,000	215,169,000	216,090,000	215,238,000	173,535,000	262,512,000	161,250,000	169,243,000	131,891,000	124,280,000	122,723,000
S&GA Expenses	-4.0%	73,272,000	76,291,000	80,886,000	88,449,000	86,914,000	92,717,500	80,118,000	79,892,000	73,271,000	86,548,000	69,252,000	68,878,000	61,095,000	75,456,000	57,840,000	53,659,000	58,209,000	63,497,500	49,284,000	49,215,000	40,544,000
R&D Expenses	-4.3%	116,129,000	121,353,000	164,212,000	185,874,000	195,124,000	188,693,500	165,462,000	157,263,000	140,078,000	149,844,000	130,845,000	125,482,000	134,513,000	118,013,000	92,998,000	176,525,000	90,107,000	81,831,000	63,076,000	59,979,000	52,566,000
EBITDA Margin	11.7%	-0.40	-0.45	-0.62	-0.60	-0.56	-0.63	-0.60	-0.71	-0.75	-0.83	-0.76	-0.62	-	-	-	-	-	-	-	-	-
Interest Expenses	73.7%	3,666,000	2,111,000	11,710,000	9,354,000	12,956,000	5,784,000	4,406,000	2,143,000	6,130,000	-1,000	4,407,000	-	5,182,000	-	4,516,000	408,000	4,878,000	651,000	3,931,000	-	3,111,000
Income Taxes	646.5%	6,880,000	-1,259,000	-33,620,000	-38,596,000	3,969,000	-18,804,000	-17,893,000	3,392,000	4,835,000	4,657,500	-36,000	488,000	451,000	12,634,000	22,288,000	84,000	222,000	10,644,000	-344,000	774,000	576,000
Earnings Before Taxes	46.1%	-84,696,000	-157,051,000	-166,590,000	-237,479,000	-134,990,000	-189,693,000	-127,208,000	-148,695,000	-121,891,000	-138,607,500	-133,660,000	-117,882,000	-128,191,000	-61,720,000	-47,404,000	-181,343,000	-112,465,000	-67,033,000	-60,341,000	-41,015,000	-71,537,000
EBT Margin	6.2%	-0.70	-0.74	-0.91	-0.84	-0.78	-0.84	-0.77	-0.88	-0.90	-0.96	-0.90	-0.75	-	-	-	-	-	-	-	-	-
Net Income	41.2%	-91,576,000	-155,792,000	-132,970,000	-198,883,000	-138,959,000	-170,889,000	-109,315,000	-152,087,000	-126,726,000	-143,265,000	-133,624,000	-118,370,000	-128,642,000	-74,354,000	-69,692,000	-181,427,000	-112,687,000	-77,677,000	-59,997,000	-41,789,000	-72,113,000
Net Income Margin	6.5%	-0.62	-0.67	-0.80	-0.75	-0.74	-0.80	-0.76	-0.90	-0.92	-0.97	-0.92	-0.83	-	-	-	-	-	-	-	-	-
Free Cashflow	157.8%	61,173,000	-105,854,000	-20,876,000	-20,365,000	-39,761,000	-174,585,000	-43,427,000	-63,942,000	-106,716,000	-77,566,000	-57,034,000	-39,119,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-5.6%	1,790	1,896	1,260	1,338	1,609	1,706	1,576	1,804	1,800	1,938	2,007	2,059	2,112	2,208	2,181	1,477	1,546	1,624	1,641	1,292	1,284
Current Assets	-4.1%	1,169	1,219	540	590	613	694	517	695	774	954	1,011	1,066	1,122	1,232	1,244	605	692	779	807	475	479
Cash Equivalents	-4.9%	565	594	165	208	167	280	121	174	152	197	197	185	154	216	441	166	131	296	531	136	201
Inventory	-1.7%	30.00	31.00	36.00	32.00	27.00	22.00	15.00	15.00	15.00	16.00	16.00	16.00	16.00	19.00	19.00	18.00	19.00	19.00	17.00	17.00	16.00
Net PPE	6.5%	93.00	87.00	85.00	82.00	79.00	73.00	67.00	65.00	59.00	53.00	46.00	43.00	37.00	34.00	28.00	27.00	26.00	22.00	18.00	15.00	15.00
Goodwill	0.0%	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00
Liabilities	-1.1%	2,684	2,714	1,931	1,917	2,066	2,053	1,803	1,986	1,890	1,937	1,902	1,862	1,819	1,726	1,670	904	1,017	1,029	978	803	771
Current Liabilities	-4.7%	575	603	492	476	442	406	420	567	477	509	465	291	251	277	254	202	218	236	184	174	143
Long Term Debt	0.1%	285	284	573	573	572	572	283	282	282	282	282	430	430	309	303	297	295	294	293	136	138
LT Debt, Current	-	-	-	-	-	-	-	-	150	150	150	149	-	-	8.00	-	18.00	20.00	20.00	20.00	20.00	17.00
LT Debt, Non Current	-100.0%	-	284	573	573	572	572	283	282	282	282	282	430	430	309	303	297	295	294	293	136	138
Shareholder's Equity	-9.2%	-893	-818	-	-	-457	-347	-	-	-	1.00	105	197	293	482	511	572	529	594	664	489	513
Retained Earnings	-2.8%	-3,375	-3,283	-3,127	-2,994	-2,795	-2,656	-2,486	-2,376	-2,224	-2,097	-1,954	-1,821	-1,702	-1,628	-1,554	-1,484	-1,303	-1,190	-1,112	-1,052	-1,011
Additional Paid-In Capital	0.8%	2,487	2,466	2,447	2,417	2,340	2,305	2,223	2,184	2,153	2,124	2,093	2,064	2,034	-123	2,101	2,067	1,834	1,795	1,776	1,540	1,523
Shares Outstanding	1.2%	77.00	76.00	75.00	75.00	74.00	73.00	71.00	71.00	71.00	70.00	70.00	70.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,331	-	-	-	2,130	-	-	-	2,191	-	-	-	2,923	-	-	-	2,567	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	170.6%	71.00	-100	-14.52	-14.12	-29.49	-165	-38.04	-55.24	-97.40	-68.84	-51.19	-31.14	-100	-64.37	27.00	-74.81	-81.55	-10.21	-15.50	-30.52	-42.41
Share Based Compensation	11.3%	18.00	17.00	27.00	29.00	29.00	27.00	29.00	28.00	27.00	26.00	26.00	26.00	26.00	21.00	17.00	17.00	15.00	11.00	10.00	11.00	9.00
Cashflow From Investing	-21.7%	-114	-94.42	-29.60	-23.75	-28.97	32.00	136	72.00	49.00	68.00	65.00	56.00	30.00	-208	-394	142	-101	-229	30.00	-38.17	-150
Cashflow From Financing	-99.9%	1.00	620	3.00	18.00	4.00	303	-139	4.00	1.00	4.00	3.00	4.00	10.00	40.00	643	-32.92	18.00	2.00	382	3.00	226

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PTCT Income Statement

2024-03-31

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Revenue	$ 210,118	$ 220,382
Operating expenses:
Cost of product sales, excluding amortization of acquired intangible assets	14,740	14,144
Amortization of intangible assets	51,530	39,415
Research and development	116,129	195,124
Selling, general and administrative	73,272	86,914
Change in the fair value of contingent consideration	(100)	2,400
Total operating expenses	255,571	337,997
Loss from operations	(45,453)	(117,615)
Interest expense, net	(40,834)	(27,331)
Other income, net	1,591	9,956
Loss before income tax expense	(84,696)	(134,990)
Income tax expense	(6,880)	(3,969)
Net loss attributable to common stockholders	$ (91,576)	$ (138,959)
Weighted-average shares outstanding:
Basic	76,496,127	73,729,284
Diluted	76,496,127	73,729,284
Net loss per share-basic and diluted (in dollars per share)
Basic	$ (1.20)	$ (1.88)
Diluted	$ (1.20)	$ (1.88)
Net product revenue
Revenues:
Revenue	$ 177,604	$ 187,557
Collaboration revenue
Revenues:
Revenue		6
Royalty revenue
Revenues:
Revenue	31,154	30,831
Manufacturing revenue
Revenues:
Revenue	$ 1,360	$ 1,988

PTCT Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 548,355	$ 594,001
Marketable securities	336,458	282,738
Trade and royalty receivables, net	197,660	160,822
Inventory, net	30,058	30,577
Prepaid expenses and other current assets	56,207	150,491
Total current assets	1,168,738	1,218,629
Fixed assets, net	92,779	87,089
Intangible assets, net	330,040	379,497
Goodwill	82,341	82,341
Operating lease ROU assets	91,186	91,896
Deposits and other assets	24,545	36,246
Total assets	1,789,629	1,895,698
Current liabilities:
Accounts payable and accrued expenses	330,924	391,983
Deferred revenue		801
Operating lease liabilities- current	14,572	13,002
Finance lease liabilities- current	1,948	3,000
Liability for sale of future royalties - current	227,102	194,314
Total current liabilities	574,546	603,100
Long-term debt	284,512	284,213
Contingent consideration payable	36,200	36,300
Deferred tax liability	55,904	55,905
Operating lease liabilities- noncurrent	104,837	97,627
Finance lease liabilities- noncurrent	15,574	17,184
Liability for sale of future royalties- noncurrent	1,611,831	1,619,783
Other long-term liabilities	141	141
Total liabilities	2,683,545	2,714,253
Stockholders' deficit:
Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 76,653,960 shares at March 31, 2024. Authorized 250,000,000 shares; issued and outstanding 75,708,889 shares at December 31, 2023	76	75
Additional paid-in capital	2,486,722	2,466,233
Accumulated other comprehensive loss	(5,560)	(1,285)
Accumulated deficit	(3,375,154)	(3,283,578)
Total stockholders' deficit	(893,916)	(818,555)
Total liabilities and stockholders' deficit	$ 1,789,629	$ 1,895,698

About PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

CEO	Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS
WEBSITE	ptcbio.com
INDUSTRY	Biotechnology
EMPLOYEES	1402

PTC Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for PTC Therapeutics Inc? What does PTCT stand for in stocks?

PTCT is the stock ticker symbol of PTC Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PTC Therapeutics Inc (PTCT)?

As of Tue Apr 30 2024, market cap of PTC Therapeutics Inc is 2.47 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTCT stock?

You can check PTCT's fair value in chart for subscribers.

What is the fair value of PTCT stock?

You can check PTCT's fair value in chart for subscribers. The fair value of PTC Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PTC Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PTCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PTC Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PTCT is over valued or under valued. Whether PTC Therapeutics Inc is cheap or expensive depends on the assumptions which impact PTC Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTCT.

What is PTC Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, PTCT's PE ratio (Price to Earnings) is -4.26 and Price to Sales (PS) ratio is 2.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTCT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on PTC Therapeutics Inc's stock?

In the past 10 years, PTC Therapeutics Inc has provided 0.059 (multiply by 100 for percentage) rate of return.